The study included the largest data set of 112,269 hospitalized patients with moderate COVID-19. The data included patients enrolled between January 1, 2020 and September 10, 2021, at 64 health systems in the United States participating in the National Institutes of Health’s (N3C) National COVID Collaborative Group (N3C). ).
The researchers found a 1.6% reduction in mortality with aspirin on the first day of hospital admission in patients with moderate disease and less blood clot formation. They also found that elderly patients and patients with one or more comorbidities particularly benefit from early aspirin treatment.
Keith Crandall, Director of the Institute for Computational Biology (CBI) at George Washington University, which helped assemble and import GW’s data into the NIH database and manage the dataset into a usable format used for statistical analysis, said, “This study is critical to providing physicians and patients with accessible and effective COVID-19 treatments to help reduce mortality on admission and helping people recover from this potentially devastating disease.”
Chow and his team have focused on this topic since the beginning of the pandemic. Their first study was published in April 2021 and the second study was published in November 2021.